News | June 07, 2011

Solution for Expanding Clinical Utilization in Nuclear Cardiology

June 7, 2011 – At the Society of Nulear Medicine (SNM) 2011 meeting this week, Siemens Healthcare demonstrated how users of the Symbia S and Symbia T series, single-photon emission computed tomography (SPECT) and SPECT•CT systems, respectively, are taking advantage of IQ•SPECT, to dramatically reduce the length of imaging protocols. A field-upgradeable combination of hardware and software, IQ•SPECT is helping nuclear cardiologists cut the cardiac imaging protocol from approximately 20 minutes to less than five minutes. These shortened exams enable a sustainable approach to nuclear cardiology that potentially enables decreased radiation dose to patients, assists to make the procedure more tolerable for the elderly, provides high quality diagnostic information, and allows users to better utilize an imaging resource that is hampered by limited availability of the key radiotracer.

“There is a significant difference between a four-minute SPECT scan with IQ•SPECT and a conventional 20-minute SPECT because many older patients cannot tolerate a longer scan; in our practice IQ•SPECT provides the opportunity to obtain quality SPECT imaging information in cases where it would not have been possible to even attempt imaging,” said James R. Corbett, M.D., director, cardiovascular nuclear medicine, professor, departments of internal medicine and radiology, University Hospital, University of Michigan Health System, Ann Arbor.

In recognition of its market-differentiating features, Siemens recently received the Product Differentiation Excellence Award, Nuclear Cardiology, North America, 2011, from industry analyst group Frost & Sullivan.

“Despite the benefits to clinical decision making conferred by the modality, the cardiac SPECT market has been faced with challenging circumstances that have led to a significant shift in the traditional provider setting,” said Sangeetha Prabakar, industry analyst, Frost & Sullivan. “With IQ•SPECT, Siemens has delivered a solution that addresses the cost sensibilities engendered by decreased reimbursement and the relative scarcity of the radiotracer.”

IQ•SPECT brings enhanced value to patients, medical facilities, and cardiologists and is an ideal fit for hospital-based cardiology imaging needs. It has been shown to reduce radiotracer doses by up to 50 percent, thus translating into lower amounts of radiation for the patient, and potential increased cost savings and access to radiotracer supply for the medical facility.

IQ•SPECT utilizes SmartZoom collimators, which focus on the heart, collecting up to four times more counts than conventional, large-bore, parallel-hole collimators; cardio-centric orbit acquisition, which ensures that the heart is always in the SmartZoom collimator’s “sweet spot,” or magnification zone, as opposed to the gantry’s mechanical center; and, lastly, a proprietary 3-D reconstruction algorithm that models the position of each of the 48,000 collimator holes on each detector, allowing state-of-the-art distant-dependent isotropic (3-D) resolution recovery, CT-based attenuation correction (when using SPECT•CT), and energy window-based scatter correction.

For more information: www.siemens.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.